Smallwood Wealth Investment Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$627K Sell
2,493
-9
-0.4% -$1.94K 0.27% 39
2026
Q1
$544K Buy
2,502
+40
+2% +$8.87K 0.29% 43
2025
Q4
$563K Buy
2,462
+9
+0.4% +$2.05K 0.29% 43
2025
Q3
$568K Sell
2,453
-1
-0% -$204 0.29% 46
2025
Q2
$456K Buy
2,454
+9
+0.4% +$1.67K 0.26% 49
2025
Q1
$512K Hold
2,445
0.32% 43
2024
Q4
$434K Hold
2,445
0.3% 47
2024
Q3
$483K Buy
2,445
+61
+3% +$11.4K 0.34% 40
2024
Q2
$409K Hold
2,384
0.32% 45
2024
Q1
$434K Hold
2,384
0.34% 44
2023
Q4
$369K Buy
2,384
+42
+2% +$6.12K 0.31% 46
2023
Q3
$349K Buy
2,342
+258
+12% +$37.9K 0.32% 45
2023
Q2
$281K Hold
2,084
0.25% 52
2023
Q1
$332K Sell
2,084
-525
-20% -$80.3K 0.31% 46
2022
Q4
$422K Sell
2,609
-72
-3% -$11K 0.36% 48
2022
Q3
$360K Buy
2,681
+759
+39% +$109K 0.32% 53
2022
Q2
$294K Buy
1,922
+593
+45% +$90.6K 0.3% 51
2022
Q1
$215K Buy
+1,329
New +$193K 0.2% 51

Other funds holding ABBV

Smallwood Wealth Investment Management's ABBV Position: Q2 2026 in Review

Smallwood Wealth Investment Management reduced its AbbVie (ABBV) stake by 0.36% in Q2 2026, selling an estimated $1.94K and leaving 2,493 shares worth $627K. The position accounts for 0.27% of the portfolio, ranked #39.

Smallwood Wealth Investment Management first reported a position in ABBV in Q1 2022 and has held it in 18 quarters since. 2,151 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Smallwood Wealth Investment Management held 2,493 shares of AbbVie worth $627K as of Q2 2026.
  • Smallwood Wealth Investment Management sold 9 AbbVie shares in Q2 2026, an estimated $1.94K.
  • AbbVie made up 0.27% of Smallwood Wealth Investment Management's portfolio in Q2 2026, its #39 holding.
  • Smallwood Wealth Investment Management first reported a position in AbbVie in Q1 2022 and has held it in 18 quarters since.
  • 2,151 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Smallwood Wealth Investment Management's 13F filing for Q2 2026, filed 23 Jul 2026.